Primary resistance occurs when patients do not respond to immunotherapy because of tumor-extrinsic features associated with immunodeficiencies or tumor-intrinsic features such as a lack of antigen or insensitivity to T-cell responses, e.g., due to a defective IFN-γ-dependent pathway [66, 97]. The gene discussed is IFNG; the disease is neoplasm.